The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | MRD testing platforms for lung cancer
Christian Rolfo, MD, PhD, MBA, The Tisch Cancer Institute at Mount Sinai, New York, NY, discusses the role of circulating tumor DNA (ctDNA) and minimal residual disease (MRD) monitoring in lung cancer. Tumor-informed ctDNA assays enable personalized replication of a phylogenetic tree to monitor patient relapse via a liquid biopsy and MRD monitoring using ctDNA has additionally been utilized in monitoring patient outcomes in the Phase III MERMAID trial (NCT04385368). This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
